Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12608000504314
ACTRN12608000504314
Completed
Phase 4

Pilot study examining whether daily administration of 3mg melatonin alters sleep architecture in complete quadriplegia

Austin Health0 sites5 target enrollmentSeptember 30, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Austin Health
Enrollment
5
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 30, 2008
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Complete (motor and sensory) quadriplegia (T1 or higher lesion)

Exclusion Criteria

  • •Major psychological or psychiatric disturbances, Neurological damage other than spinal cord injury, Other significant co\-morbidity, Beta blockers.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A trial comparing effect of two different regimes of iron supplementation on markers of oxidative stress and anti-oxidant status in children with iron deficiency anemiaHealth Condition 1: null- Iron deficiency anemia
CTRI/2010/091/001102il72
Recruiting
Phase 3
Mifepristone ovarian function studyThe effect of administering a progestogen receptor modulator with or without oestrogen on the ovarian function and quality of cervical mucus in women using the progestogen-only sub-dermal contraceptive, Implanon.Other - Cervical (Cervix)
ACTRN12605000698673FPA Health40
Completed
Phase 2
A randomized phase II study of daily administrations versus alternate-day administrations of S-1 with completely resected pathological stage I (T>2cm) of non-small cell lung cancernon-small cell lung cancer
JPRN-UMIN000011994Setouchi Lung Cancer Group93
Active, not recruiting
Phase 1
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus
EUCTR2014-001540-38-GBovo Nordisk A/S957
Active, not recruiting
Phase 1
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusObesityMedDRA version: 18.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-001540-38-BEovo Nordisk A/S935